Gritstone Bio Revenue 2017-2024 | GRTSQ
Gritstone Bio revenue from 2017 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Gritstone Bio Annual Revenue
(Millions of US $) |
| 2023 |
$16 |
| 2022 |
$20 |
| 2021 |
$48 |
| 2020 |
$4 |
| 2019 |
$4 |
| 2018 |
$1 |
| 2017 |
$ |
| 2016 |
$ |
Gritstone Bio Quarterly Revenue
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$10 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$2 |
| 2022-12-31 |
$4 |
| 2022-09-30 |
$3 |
| 2022-06-30 |
$5 |
| 2022-03-31 |
$7 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$3 |
| 2021-06-30 |
$3 |
| 2021-03-31 |
$40 |
| 2020-12-31 |
$1 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$1 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$1 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$1 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
